#361 Advanced Lipidology
The Curbsiders Internal Medicine Podcast
00:00
Is Clizarin a Good Anti-Sense Agent or a Pcsk9 Inhibitor?
The advantage of in clizarin is that it's every six months so for younger patients the thought is it might really help with adherence. The PCSK9 monoclonal antibodies also lower lipertil A by 25% which is why these new therapies are still being studied and they're not approved i'm just letting the audience know that they're out there being studied.
Transcript
Play full episode
